March 25, 2022: “Construction begins on a new state-of-the-art manufacturing facility at Kent Science Park designed to support the manufacture of regulatory approved cannabis-based medicines
This represents a significant commitment to the UK by GW Pharmaceuticals, now part of Jazz Pharmaceuticals, investing $100 million (£75m) and creating more than 100 highly skilled jobs
LONDON, March 25, 2022 /PRNewswire/ — Jazz Pharmaceuticals plc and its subsidiary, GW Pharmaceuticals (“GW”) – a world leader in discovering, developing and delivering regulatory approved cannabis-based medicines –announced the official initiation of construction of its new, state-of-the-art manufacturing facility at Kent Science Park (KSP) in Sittingbourne.”
http://investor.jazzpharma.com/news-releases/news-release-details/jazz-pharmaceuticals-announces-significant-new-investment-uk
